46. 悪性関節リウマチ
[臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03394131 (ClinicalTrials.gov) | July 1, 2017 | 25/12/2017 | ?Efficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients | Treatment of Carpal Tunnel in Rheumatoid Arthritis | Treatment Resistant Carpal Tunnel in RA Patients | Drug: Hylase;Drug: Insulin;Other: saline | Assiut University | NULL | Unknown status | 20 Years | 80 Years | All | 90 | N/A | Egypt |
2 | NCT01132118 (ClinicalTrials.gov) | June 2010 | 25/5/2010 | Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis | Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis | Rheumatoid Arthritis;Insulin Resistance | Drug: Hydroxychloroquine | Brigham and Women's Hospital | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | N/A | All | 30 | Phase 3 | United States |
3 | NCT00763139 (ClinicalTrials.gov) | April 2009 | 26/9/2008 | Inflammation and Insulin Resistance in Rheumatoid Arthritis | Inflammation and Insulin Resistance in Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Pioglitazone;Drug: Placebo | Vanderbilt University | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | N/A | All | 34 | N/A | United States |
4 | EUCTR2005-000492-18-IT (EUCTR) | 16/12/2004 | 09/11/2007 | Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome | Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome | Metabolic Syndrome and Rheumatoid Arthritis MedDRA version: 6.1;Level: SOC;Classification code 10021428 | Trade Name: REMICADE*EV F 100MG+F 2ML INN or Proposed INN: Infliximab | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
5 | NCT00034060 (ClinicalTrials.gov) | April 2002 | 19/4/2002 | The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept | Suppression of the Growth Hormone/ Insulin-Like Growth Factor-1 (GH/IGF-1) Axis in Women With Rheumatoid Arthritis | Rheumatoid Arthritis;Healthy | Drug: Etanercept | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NULL | Completed | N/A | N/A | Female | 36 | Phase 2 | United States |